Numbers needed to treat derived from meta-analysis: A word of caution

Evidence-Based Medicine

Volumn 8, Issue 2, 2003, Pages 36-37

  Marx, Arthur ^a   Bucher, Heiner C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID;

CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL STUDY; CONFIDENCE INTERVAL; EVIDENCE BASED MEDICINE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; META ANALYSIS; METHODOLOGY; MORTALITY; NOTE; OUTCOMES RESEARCH; PHYSICIAN; RANDOMIZATION; RISK ASSESSMENT; STANDARDIZATION; TREATMENT OUTCOME;

EID: 0037368634     PISSN: 13565524     EISSN: None     Source Type: Journal    
DOI: 10.1136/ebm.8.2.36     Document Type: Note

References (13)

1. Deeks JJ, Altman DG. Effect measures for meta-analysis of trials with binary outcomes. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care. 2d ed. London: BMJ Publishing Group, 2001:313-35.
2. Ebrahim S. Numbers needed to treat derived from meta-analyses: pitfalls and cautions. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care. 2d ed. London: BMJ Publishing Group, 2001:386-99.
3. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
4. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
5. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-12.
6. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. BMJ 1999;318:548-51.
7. Lubsen J, Hoes A, Grobbee D. Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained. Lancet 2000;356:1757-9.
8. Guyatt GH, Cook DJ, Jaeschke R. How should clinicians use the results of randomized trials? [Editorial]. ACP J Club 1995;122:A 12-3.
9. Glasziou P, Guyatt GH, Dans AL, et al. Applying the results of trials and systematic reviews to individual patients [Editorial]. Evidence-Based Medicine 1998;3:165-6.
10. McAlister FA. Commentary: relative treatment effects are consistent across the spectrum of underlying risks...usually. Int J Epidemiol 2002;31:76-7.
11. Simon JA. Review: n-3 polyunsaturated fatty acids reduce fatal MI, sudden death, and overall mortality in coronary heart disease. Evidence-Based Medicine 2002;7:142.
12. Bucher HC, Hengstler P, Schindler C, et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002;112:298-304.
13. Straus SE. Individualizing treatment decisions. The likelihood of being helped or harmed. Eval Health Prof 2002;25:210-24.